glp-1 injections sf Semaglutide for Chronic Weight Management
Description
While incretin-based therapies have been commercially available since 2005, most clinical trials only report short term outcomes
Do not take close to bedtime
Understanding these potential effects helps patients and clinicians anticipate and manage treatment-related changes effectively
Published research and clinical observation suggest lean mass can account for roughly a quarter to nearly forty percent of total weight lost on GLP-1 medications, compared to about 10-25% with diet and resistance training alone
Read Next
EHR data suggest tirzepatide outdoes semaglutide for weight loss
